Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Invion ( (AU:IVX) ) has issued an update.
Invion has advanced its clinical program for INV043 in non-melanoma skin cancer by progressing to the final phase of its current trial and expanding enrolment to patients with basal cell carcinoma. This move follows approval from the Safety Review Committee, which was contingent on favourable safety data from earlier squamous cell carcinoma cohorts.
New preliminary data from six additional squamous cell carcinoma patients showed no dose-limiting toxicities, no treatment-related pain and strong tolerability relative to existing photodynamic therapies. The cohort also demonstrated statistically significant lesion size reductions, complete resolution in some cases and consistent fluorescence signals, reinforcing the theragnostic potential of INV043 and supporting Invion’s Phase II planning and a future anogenital trial using the same formulation.
More about Invion
Invion Limited is an Australia-based biotechnology company focused on developing INV043, a topical photodynamic therapy for non-melanoma skin cancers. The company targets conditions such as squamous cell carcinoma and basal cell carcinoma, aiming to address large, underserved dermatology markets with theragnostic treatment approaches.
Average Trading Volume: 79,546
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$5.82M
For detailed information about IVX stock, go to TipRanks’ Stock Analysis page.